Search Results
Your search for The ASCO Post,The ASCO Post matches 17617 pages
Showing 14551 - 14600NewYork-Presbyterian/Columbia University Medical Center Opens Irving Radiation Oncology Center
NewYork-Presbyterian/Columbia University Medical Center has opened its new Irving Radiation Oncology Center, part of the medical center’s Herbert Irving Comprehensive Cancer Center. The 12,500-square-foot facility provides precision radiation therapies and advanced diagnostic imaging for children...
Ocular Melanoma Research Fellowship Opportunity Announced
The American Association for Cancer Research (AACR) and the Ocular Melanoma Foundation (OMF) are pleased to announce a new partnership to provide a grant opportunity for researchers focused on ocular melanoma, which is diagnosed in approximately 2,000 adults in the United States each year....
Mount Sinai Health System Appoints New Director and Faculty to Division of Gynecologic Oncology
Peter R. Dottino, MD, has been appointed Director of the Division of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Reproductive Medicine at the Mount Sinai Health System in New York. He also holds an appointment as Associate Clinical Professor at the Icahn School of Medicine ...
CTCA Names National Director for HIPEC Research
Cancer Treatment Centers of America (CTCA) has announced the appointment of Jesus Esquivel, MD, as the National Director of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). In this position Dr. Esquivel will oversee the organization’s national HIPEC research. Dr. Esquivel’s past experience...
German Analysis in Diffuse Large B-Cell Lymphoma: Hypothesis-Generating Rather Than Definitive?
In their retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in the Journal of Clinical Oncology and reviewed in this issue of The ASCO Post, Held and colleagues assessed the effects of rituximab (Rituxan) and radiotherapy in patients with aggressive B-cell...
Amy P. Abernethy, MD, PhD, to Chair CancerLinQ™ Advisory Committee
ASCO has announced that Amy P. Abernethy, MD, PhD, FACP, has agreed to chair a new CancerLinQ™ Advisory Committee within the Institute for Quality, an ASCO affiliate dedicated to innovative quality improvement programs, that will guide this multiphase effort. The advisory committee consists of...
ASCO Launches Formal Development of CancerLinQ™ System
ASCO recently announced that it has initiated development of the full CancerLinQ™ system, a groundbreaking health information technology (HIT) initiative to achieve higher-quality, higher-value cancer care with better outcomes for patients. The announcement was made at a White House Office of...
University of Chicago Names Ernst Lengyel, MD, PhD, Chair of Obstetrics and Gynecology
Ernst Lengyel, MD, PhD, was recently named Chair of the Department of Obstetrics and Gynecology at the University of Chicago. He succeeds Arthur Haney, MD, who served as Chair of the Department of Obstetrics and Gynecology since April 2003. Under the leadership of Dr. Haney, the Department...
National Human Genome Research Institute Names First Director of Division of Genomics and Society
Lawrence C. Brody, PhD, has been selected to be the first Director of the newly established Division of Genomics and Society at the National Human Genome Research Institute (NHGRI). Dr. Brody, a genetics and genomics researcher, is currently Chief of the Genome Technology Branch within NHGRI’s...
Improving Fertility Options for Patients With Cancer
Seven years ago, Teresa K. Woodruff, PhD, coined the term “oncofertility” to describe the melding of two medical specialties, oncology and reproductive endocrinology, with the goal of maximizing the reproductive potential of patients with cancer. Today, with Dr. Woodruff’s establishment of the...
FDA Grants Ofatumumab Breakthrough Therapy Designation for Previously Untreated CLL
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ofatumumab (Arzerra) in combination with chlorambucil (Leukeran) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior treatment and are inappropriate for...
New Medical Device Treats Urinary Symptoms Related to Benign Prostatic Hyperplasia
The U.S. Food and Drug Administration has authorized the marketing of the UroLift system, a permanent implant to relieve low or blocked urine flow in men age 50 and older with benign prostatic hyperplasia. As men age, the prostate can become enlarged, also known as benign prostatic hyperplasia....
Gastric Cancer: Time to Revisit Angiogenesis
Progress in the treatment of gastric cancer has lagged behind advances in other solid tumor malignancies. A modest but clear survival benefit with the use of adjuvant therapy combined with surgery has been achieved, including the use of postoperative adjuvant chemotherapy as shown in large-scale...
Has a New Standard of Care for Metastatic Pancreatic Cancer Been Established?
For a number of years following the approval of gemcitabine for advanced pancreatic cancer, one phase III clinical trial after the next failed to demonstrate a survival benefit of combination chemotherapy compared to gemcitabine alone. Even the one positive study from the mid-2000s—the PA.3 trial...
Long-Term CONKO-001 Results: Adjuvant Therapy Improves Survival
From 12% to 15% of the approximately 45,000 patients diagnosed with pancreas adenocarcinoma undergo a potentially curative resection each year in North America, translating into roughly 5,000 to 7,000 patients who are candidates for adjuvant therapy. About 80% of these patients will relapse and...
Benefits and Controversies in Survivorship Care Plans
Since the Institute of Medicine’s (IOM’s) 2005 report, From Cancer Patient to Cancer Survivor: Lost in Translation,1 survivorship plans have received growing attention. In short, a survivorship care plan is the record of a patient’s cancer history and recommendations for follow-up care. At ASCO’s...
SIDEBAR: FDA Drug Approvals, 2013
Ibrutinib (Imbruvica) for mantle cell lymphoma Obinutuzumab (Gazyva) for chronic lymphocytic leukemia Pertuzumab (Perjeta) for breast cancer Paclitaxel protein-bound particles (Abraxane) for pancreatic adenocarcinoma Afatinib (Gilotrif) for non-small cell lung cancer, with Therascreen EGFR...
FDA Approves Ibrutinib for Mantle Cell Lymphoma
The U.S. Food and Drug Administration has approved ibrutinib (Imbruvica) to treat patients with mantle cell lymphoma, a rare and aggressive form of non-Hodgkin lymphoma representing about 6% of all non-Hodgkin lymphoma cases in the United States. By the time mantle cell lymphoma is diagnosed, it...
Brentuximab and PET-Adapted Salvage May Eliminate Toxic Chemotherapy for Refractory Hodgkin Lymphoma
Relapsed and refractory transplant-eligible Hodgkin lymphoma patients who achieve complete responses after treatment with brentuximab vedotin (Adcetris) can often avoid more toxic salvage chemotherapy, according to investigators from Memorial Sloan-Kettering Cancer Center, New York....
SIDEBAR: Addition of Novel Agents May Improve Outcomes With ABVD
In North America, the standard front-line treatment for advanced Hodgkin lymphoma is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), but this regimen is not effective in all patient subsets. To improve upon the regimen’s efficacy, researchers are evaluating new combinations, said Stephen...
Brentuximab Vedotin Improves Response Rates to ABVD in Hodgkin Lymphoma
For the front-line treatment of advanced Hodgkin lymphoma, ABVD is a standard treatment, but not all patients have good outcomes with this regimen. The addition of brentuximab vedotin (Adcetris), or its substitution for bleomycin, produces high complete response rates but with a moderate increase...
Response-Guided Neoadjuvant Therapy for Breast Cancer: A Promising Model Warranting Additional Investigation
GeparTrio was an innovative phase III trial conducted by the German Breast Group, enrolling over 2,000 women with early breast cancer who were candidates for neoadjuvant chemotherapy. Patients with evidence of early response, defined as reduction in clinical tumor size by 50% or more, following two ...
The ASCO Post Replies
We appreciate Dr. Herrmann’s concerns in regard to conflict of interest. The ASCO Post makes every effort to present news and data in an objective and fair manner. Often we invite an independent expert in a particular area to share his or her perspective to lend more insight to a report. We...
Perception of Bias
I am a veteran member of ASCO (> 33 years) and a regular reader of The ASCO Post Evening News, which usually provides very interesting information. A recent issue contained an article about a review presented by Tony Reid, MD, PhD, at a Best of ASCO meeting on “Important Findings in Metastatic...
Young Tobacco Consumers Frequently Use Products Other Than Cigarettes
“A substantial proportion of youth tobacco use occurs with products other than cigarettes, so monitoring and prevention of youth tobacco use needs to incorporate other products, including new and emerging products,” according to the Morbidity and Mortality Weekly Report, published by the Centers...
Steven T. Rosen, MD, Named Provost and Chief Scientific Officer of City of Hope
City of Hope has selected Steven T. Rosen, MD, the Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, as its first Provost and Chief Scientific Officer. Dr. Rosen will set the scientific direction of City of Hope as it embarks on a...
SIDEBAR: Expect Questions From Patients
Not discussing the costs of medical interventions could result in “financial toxicity” for patients who have trouble paying out-of-pocket costs, as well as problems adhering to expensive treatment regimens. “The problem is perhaps starkest in cancer care, but it applies to all complex illness,”...
Disclosing Medical Costs Can Help Avoid 'Financial Toxicity'
High costs of cancer treatments can be an “undisclosed toxicity” that can harm a patient’s overall health and well-being, according to an article in The New England Journal of Medicine.1 High medical bills can not only cause stress and anxiety but may also compel patients to cut back on spending...
Focus on the Massachusetts Society of Clinical Oncologists
The Massachusetts Society of Clinical Oncologists (MSCO) is among the oldest and largest of ASCO’s State Affiliates. Based in the same building as the Massachusetts Medical Society in Waltham, MSCO was founded in 1985 and has a growing membership of 160 members, including medical, surgical, and...
Dr. Weisenthal Replies
Dr. Mason states that I implied that Dr. Telli supports the routine application of chemosensitivity assays. I have no knowledge regarding Dr. Telli’s views on this subject, nor did I in any way attempt to represent her views, much less imply that she was supportive of anything relating to...
Conflict of Interest Reconsidered
I read with interest the letter from Larry Weisenthal, MD, PhD, on “Platinum-Based Treatment of Triple-Negtive Breast Cancer,” which appeared in the October 15 issue of The ASCO Post. Dr. Weisenthal seems to be suggesting that an article in the September issue, regarding a Best of ASCO presentation ...
NIH Announces New Co-Chairs of Panel on Antiretroviral Guidelines
The National Institutes of Health recently announced several changes in leadership on the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. The panel, a working group of the NIH Office of AIDS Research Advisory Committee (OARAC), consists of...
Oncology Meetings
January 2014 AACR-IASLC Joint Conference on the Molecular Origins of Lung CancerJanuary 6-9 • San Diego, CaliforniaFor more information: www.aacr.org 2014 Gastrointestinal Cancers SymposiumJanuary 16-18 • San Francisco, CaliforniaFor more information: www.gicasym.org 10th Annual Clinical...
The Quest to Optimize Personalized Therapies for Cancer
In the late 1980s, Brian J. Druker, MD, was investigating the BCR-ABL tyrosine kinase as a target for therapeutic intervention for chronic myeloid leukemia (CML) in a laboratory at Dana-Farber Cancer Institute in Boston. By 1993, Dr. Druker had moved to Oregon Health & Science University in...
Society for Integrative Oncology Is Helping to Advance Evidence-Based, Comprehensive Integrative Health Care
Heather Greenlee, ND, PhD, was named President of the Society for Integrative Oncology (SIO) at the organization’s 10th International Conference in October. Dr. Greenlee is Assistant Professor in the Department of Epidemiology at the Mailman School of Public Health at Columbia University in New...
FDA Grants Regular Approval to Crizotinib for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has granted regular approval for crizotinib (Xalkori) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The approval was based...
FDA Approves Sorafenib to Treat Late-Stage Differentiated Thyroid Cancer
The U.S. Food and Drug Administration recently expanded the approved uses of sorafenib (Nexavar) to treat late-stage differentiated thyroid cancer. The new indication is for patients with locally recurrent or metastatic, progressive differentiated thyroid cancer that no longer responds to...
American Association for Advancement of Science Elects New Fellows
The American Association for the Advancement of Science (AAAS) has identified 388 individuals who have been named AAAS Fellows. These individuals have been recognized by their peers for their efforts to advance science or its applications. The new AAAS Fellows, whose names were published in the...
NCI-Led Scientists Develop Criteria for 'Omics' Tests Used in Clinical Investigations
High-throughput “omics” technologies that generate molecular profiles on tumor specimens are increasingly being incorporated into clinical trials, but some of these assays have not been well validated, leading many in the research community to question their fitness for use in patient-care...
Valganciclovir in Glioblastoma, Selection Bias, and Flawed Conclusions
As reviewed in this issue of The ASCO Post, Söderberg-Nauclér et al from the Karolinska Institute have written a provocative letter to The New England Journal of Medicine suggesting that long-term administration of valganciclovir (Valcyte), a drug that targets cytomegalovirus (CMV), improves...
Correctly Assessing Pain Progression and Quality-of-Life Deterioration in Metastatic Castration-Resistant Prostate Cancer
The therapeutic landscape for the treatment of castration-resistant prostate cancer has changed dramatically in the past 4 years, as five new agents affecting different aspects of the malignant process were proven to prolong life. The results are a great benefit to patients, but at the same time...
Jame Abraham, MD, Moves to Taussig Cancer Institute
Jame Abraham, MD, has been appointed to the positions of Director, Taussig Cancer Institute Breast Oncology Program, and Co-Director of the Cleveland Clinic Multidisciplinary Breast Cancer Program. Dr. Abraham is the former Medical Director of the West Virginia University Mary Babb Randolph Cancer ...
Adjuvant Trastuzumab Duration: When Is Enough, Enough?
The duration of adjuvant systemic chemotherapy for breast cancer has been a subject of investigation, scrutiny, and meta-analysis.1,2 With the appreciation that prolonged regimens of cytotoxic chemotherapy of, for example, 1 to 2 years in duration were not superior in reducing breast cancer...
Centers in Massachusetts Collaborate in Joint Center for Cancer Precision Medicine
The Joint Center for Cancer Precision Medicine, a collaborative initiative among Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard, has been established to create “precision medicine treatment pathways” for patients...
Now Available: Communicating with Cancer Patients
The European Society of Medical oncology has endorsed the newly released book, Communicating with Cancer Patients, written by Professor John F. Smyth, MD, of the University of Edinburgh, and designed for trainee oncologists, oncology nurses, and other health-care professionals involved in...
Erratum
In the November 15 issue of The ASCO Post, the article, “Strong Showing for Ado-Trastuzumab Emtansine in Advanced HER2-Positive Heavily Pretreated Breast Cancer,” contained the following errors in the reported outcomes data for the TH3RESA trial: The article incorrectly stated the median survival...
Global Oncology 2013: Disparities in Cancer Care
While much progress has been made against cancer over the last century, a new report1 presented at the 2013 European Cancer Congress brings together evidence that not every patient benefits from it, nor even has the opportunity to benefit. The economics of cancer are daunting and the current model...
Transplant Now or Later for High-Risk Aggressive Non-Hodgkin Lymphoma?
The use of high-dose chemotherapy and autologous hematopoietic blood or marrow transplantation for high-risk aggressive non-Hodgkin lymphoma has been extensively evaluated over the past few decades. This treatment was originally used only for patients with relapsed aggressive lymphoma. However, as...
S9704 Trial: Autologous Transplantation as Consolidation in Aggressive Lymphoma
Autologous bone marrow or stem cell transplantation has had an important role in the treatment of aggressive lymphoma for several decades. The important results of the PARMA study1 demonstrated that patients in first relapse who remained chemosensitive had improved progression-free and overall...
Sharing Treatment Decision-Making With Patients: Where’s the Evidence of Value?
Though certainly not new to oncologists, “shared decision-making” between doctors and patients is receiving increased attention in the medical community today. While it’s an idea with merit, Steven J. Katz, MD, MPH, a specialist in quality care issues, maintains that expectations about the...
